Denali Therapeutics Inc (DNLI) Price Targets From Analysts
The tables below show the price targets and recommendations analysts covering DNLI.
|Number of Analysts||Highest Target Price||Lowest Target Price||Average Target Price||Current Price||Upside Potential|
DNLI Broker Recommendations Summary
|Average Broker Rating||Strong Buy||Buy||Hold||Sell||Strong Sell||Analysts Issuing Recs|
Use the points listed below to better contextualize what this analyst price target and recommendations data data means for investors.
- Denali Therapeutics Inc's percent of analysts bearish on the stock is lower than nearly 100% of all US stocks.
- The variance in analysts' estimates of DNLI is less than 4.56% of stocks in the mid market cap category.
- DNLI has a greater upside potential (average analyst target price relative to current price) than 9.65% of Pharmaceutical Products stocks.
- Denali Therapeutics Inc's average analyst price target is higher than 84.21% of Pharmaceutical Products stocks.
- DNLI has a higher number of analysts covering the stock than 78.25% of Pharmaceutical Products stocks.
- The percentage of analysts bullish on the stock of DNLI is greater than 26.91% of Pharmaceutical Products stocks.
- DNLI has a lower change in bullishness amongst analysts than nearly 100% of all US stocks.
Is DNLI a Buy, Hold or Sell? See the POWR Ratings now!